AltheaDx to take DxS K-RAS test to US study centres
This article was originally published in Clinica
Oncology diagnostics company AltheaDx is set to provide study centres in the US with a K-RAS mutation test kit developed by UK firm DxS for research purposes. An agreement between the two firms will see San Diego, California-based AltheaDx use the test to support clinical research where cancer patients are assessed for their K-RAS mutation status. Manchester-based DxS said that oncologists can use the technology to study patient response to cancer therapies. The test allows clinicians to screen for mutations in the K-RAS gene which is mutated in approximately 35-45% of metastatic colorectal cancer. Financial terms of the agreement were not revealed.